Medtronic, Depuy Synthes, and Smith + Nephew are dominating the Global Orthopedic Surgical Energy Devices in 2022

Global Orthopedic Surgical Energy Devices Market is expected to grow with the CAGR of 7.8% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-orthopedic-surgical-energy-devices-market

Global orthopedic surgical energy devices market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favorable market scenario.

The major players dealing in global orthopedic surgical energy devices market are introducing wide range of product portfolio. This helped companies to maximize the sales of orthopaedic surgical energy devices and product portfolio.

For instance,

  • In December 2020, DePuy Synthes had launched the KINCISE Surgical Automated System in Europe and in Middle East and Africa. The launch had resulted an addition of a new product in the total hip replacement (THR) space. Product portfolio. It ensured availability of the product in Europe and in Middle East and Africa markets.

Orthopedic Surgical Energy Devices Market MEDTRONIC

Medtronic was founded in 1949 and has it base headquarters in Dublin, Ireland. The company focuses on treatment of various health conditions and include cardiac devices, cranial and spinal robotics, surgical tools, insulin pumps, patient monitoring systems and more by providing the product in domains such as cardiovascular, diabetes among more. The business segments are cardiac and vascular group, medical surgical, minimally invasive therapies group, restorative therapies group, and diabetes Group. The market focused category is medical surgical.

For instance,

  • In January 2020, VYAIRE had entered into a five-year term agreement with Spirosure Inc for the distribution of Spirosure’s Fenom Pro Asthma monitor in the United States, Germany, the Netherlands, and the U.K. The Fenom Pro is a gas exchange or diffusion capacity monitor, which measures FeNO, the biomarker for diagnosing and managing asthma. The five-year agreement would allow the distribution of Fenom Pro in the top diagnostic respiratory labs in the U.S. and Europe. This also increased the share of the pulmonology market in Europe in the coming years.
  • In January 2012, the Medtronic had received approval from the Food and Drug Administration (FDA) for the Aquamantys SBS 5.0 Sheathed Bipolar Sealer. The Aquamantys SBS 5.0 Sheathed Bipolar Sealer was a new product added to the spine portfolio of the company's spine portfolio. The approval received had ensured the availability and use of the Aquamantys SBS 5.0 Sheathed Bipolar Sealer, among orthopedics and spine surgeons for timely treatment of musculoskeletal disorders. It resulted in collaborations with orthopedics for the supply of the bipolar sealer.

The company has presence in North America, Europe, Middle East and Africa Asia Pacific. The subsidiaries are A&E Hangers Taiwan Co., Ltd. (Taiwan), A&E Products Group, Inc. (Delaware), Accucomp (Pty.) Ltd. (Delaware), Airox, Inc. (France) and Arterial Vascular Engineering UK Limited (UK) among more

Depuy Synthes

Depuy Synthes (subsidiary of Johnson and Johnson) was found in 1895 and is headquartered in Pennyslavania, the U.S.The company provides one of the most comprehensive Orthopedics portfolios in the world that helps heal and restore movement for the millions of patients. The product categories are craniomaxillofacial, digital and enabling technologies, foot & ankle, hand and wrist, hip, knee, power tools, shoulder and elbow, spine, thorax services. The market focused category is hip and knee.

For instance,

  • In August 2021, DePuy Synthes had launched the VELYS Digital Surgery Platform and VELYS hip navigation system at the American Academy of Orthopedic Surgeons (AAOS). The launch would result in use of digital technology in the hip navigation system in the coming years and expansion of the product line.

The subsidiaries are Codman & Shurtleff, Inc. (U.S.), Johnson & Johnson (New Zealand) Ltd, DePuy Synthes Spine, Inc. (U.S.), ACE Orthopedics (U.S.), BioMedical Enterprises, Inc. (U.S.)

Smith + Nephew

Smith+ Nephew was founded in 1856 and is headquartered in Watford, the U.K. The company focuses on designing and making technology that takes the limits off living, in order to help healthcare professionals achieve the same goal by offering products in orthopedics, sports and medicine among others. The business segments are orthopedics, sports medicine, Ear Nose Threat (ENT)  and advanced wound management. The market focused segment are orthopedics. The company offers range of product categories such as advanced wound management, orthopedic reconstruction, robotics and digital surgery, sports medicine, trauma & extremities, ear, nose & throat, material composition/ The market focused category is orthopedic reconstruction.

The company has global presence in North America, Europe, Middle East & Africa, Asia-Pacific, South America and Australia. The subsidiaries are Blue Sky Medical Group Inc. (U.S.), Exogen, Inc. (U.S.), Endocare GmbH (Germany), Plus Orthopedics France SAS (France) and Smith & Nephew (Europe) B.V (Netherlands) among others.